h. Patients of both genders must be willing to practice birth co ntrol from the time of enrollment on this study and for f our months after treatment. i. Serology: xSeronegative for HIV antibody. ( The experimental treatment bein g evaluated in this protocol depends on an intact immune system. Patients who are H IV seropositive can have decreased immune-competence and thus are less responsive t o the experimental treatment and more susceptib le to its toxicities.) xSeronegative for hepatitis B antigen, and seronegative for hepa titis C antibody. If hepatitis C antibody test is positive, then the pa tient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. j. Hematology xAbsolute neutrophil count > 1000/mm3without the support of filgrastim x:%&PP3 x3ODWHOHWFRXQWPP3 xHemoglobin > 8.0 g/dL. Subjects ma y be transfused to reach this cut-off. xCD4 count > 200/uL k. Chemistry: xSerum ALT/AST < 5.0 x ULN xSerum cUHDWLQLQHPJG L x7RWDOELOLUXELQ 2.0 mg/dL, except in patients wi th Gilbert’s Syndrome, who must have a total bilirubin 3.0 mg/dL. l.